If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...

Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

THOUSAND OAKS, Calif., March 17, 2025 /PRNewswire/ -- Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain ...

Red Lodge Mountain announced the reopening of the Willow Creek chair after completing maintenance and inspection, bringing ...

RED LODGE, Mont. – Red Lodge Mountain announced the reopening of the Willow Creek chair after completing maintenance and ...

It has been just over a year since Latigo Biotherapeutics emerged from stealth mode with $135 million in Series A financing. Now, the Thousand Oaks-based has tacked on another $150 million to its ...